Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Open-label Study of Ravulizumab in Pediatric AQP4-Ab Positive NMOSD
jRCT2031220259Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Primary endpoints: Change From Baseline in the Annualized Relapse Rate at Week 50 and Time to First Adjudicated On-trial Relapse through Week 50. Started Jul 2021; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCT2031220259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220259.